查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1361549

疟疾治疗市场 - 2018-2028F 全球产业规模、份额、趋势、机会和预测，按药物类型、药物配方、最终用户、按地区的配销通路和竞争细分

Malaria Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Drug Type, By Drug Formulation, By End User, By Distribution Channel By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 84 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

由于为消除全球疟疾而对疟疾研究和开发的持续投资，预计到 2028 年，全球疟疾治疗市场将大幅成长。根据世界卫生组织 (WHO) 统计，2020 年，全球估计有 2.29 亿疟疾病例，估计有 409,000 人死亡。

疟疾是一种可能危及生命的疾病，由寄生虫引起，透过受感染的雌性蚊子叮咬传播给人类。引起疟疾的寄生虫属于疟原虫属，其中恶性疟原虫是最致命的。疟疾在热带和亚热带地区流行，特别是在撒哈拉以南非洲，它是那里发病和死亡的主要原因。疟疾的治疗涉及使用抗疟药物，抗疟药物根据感染的类型和严重程度而有所不同。如果您怀疑自己感染了疟疾，请务必立即就医。疟疾是一种严重的疾病，如果不及时和适当的治疗，可能会致命。

  • 疟疾治疗市场，依药物类型：

以青蒿素为基础的联合疗法（ACT）

奎宁

氯奎

其他的

  • 疟疾治疗市场，依药物配方：

平板电脑

胶囊

注射剂

其他的

  • 疟疾治疗市场，依配销通路：

零售药局

医院

网路药局

  • 疟疾治疗市场，依地区：

北美洲

  • 美国
  • 墨西哥
  • 加拿大

欧洲

  • 法国
  • 德国
  • 英国
  • 西班牙
  • 义大利

亚太

  • 印度
  • 韩国
  • 日本
  • 澳洲
  • 越南
  • 印尼
  • 缅甸

南美洲

  • 巴西
  • 哥伦比亚

中东和非洲

  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及
  • 土耳其
  • 奈及利亚

竞争格局

公司概况：全球疟疾治疗市场主要公司的详细分析。

可用的客製化：

根据给定的市场资料，TechSci Research 可根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管道细目
  • 管道细分（按状态）
  • 按研究类型分類的管道细目
  • 按地区分類的管道明细
  • 临床试验热图

第 6 章：全球疟疾治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（青蒿素联合疗法 (ACT)、奎宁、氯奎、其他）
    • 依药物剂型（片剂、胶囊剂、注射剂、其他）
    • 按配销通路（零售药局、医院、网路药局）
    • 按地区
    • 按公司划分 (2022)
  • 产品图
    • 依药物类型
    • 依药物剂型
    • 按配销通路
    • 按地区

第 7 章：北美疟疾治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（青蒿素联合疗法 (ACT)、奎宁、氯奎、其他）
    • 依药物剂型（片剂、胶囊剂、注射剂、其他）
    • 按配销通路（零售药局、医院、网路药局）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 8 章：欧洲疟疾治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（青蒿素联合疗法 (ACT)、奎宁、氯奎、其他）
    • 依药物剂型（片剂、胶囊剂、注射剂、其他）
    • 按配销通路（零售药局、医院、网路药局）
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 9 章：亚太地区疟疾治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（青蒿素联合疗法 (ACT)、奎宁、氯奎、其他）
    • 依药物剂型（片剂、胶囊剂、注射剂、其他）
    • 按配销通路（零售药局、医院、网路药局）
    • 按国家/地区
  • 亚太地区：国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 越南
    • 缅甸

第 10 章：南美洲疟疾治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（青蒿素联合疗法 (ACT)、奎宁、氯奎、其他）
    • 依药物剂型（片剂、胶囊剂、注射剂、其他）
    • 按配销通路（零售药局、医院、网路药局）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚

第 11 章：中东和非洲疟疾治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（青蒿素联合疗法 (ACT)、奎宁、氯奎、其他）
    • 依药物剂型（片剂、胶囊剂、注射剂、其他）
    • 按配销通路（零售药局、医院、网路药局）
    • 按国家/地区
  • MEA：国家分析
    • 南非疟疾治疗公司
    • 沙乌地阿拉伯疟疾治疗
    • 阿联酋疟疾治疗公司
    • 土耳其疟疾治疗
    • 埃及疟疾治疗公司
    • 尼日利亚疟疾治疗公司

第 12 章：市场动态

  • 司机
    • 疟疾盛行率高
    • 意识不断增强
  • 挑战
    • 成本高且并不总是容易获得
    • 缺乏公众意识

第 13 章：市场趋势与发展

  • 数字疗法的使用
  • 增加基因检测的使用
  • 增加联合疗法的使用

第 14 章：全球疟疾治疗市场：SWOT 分析

第 15 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第16章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT分析
    • Novartis AG
    • Sanofi SA
    • Pfizer Inc
    • GlaxoSmithKline Plc
    • Merck & Co Inc
    • F. Hoffmann-La Roche AG
    • Medicines for Malaria Venture
    • 60° Pharmaceuticals, Inc
    • Cipla Limited
    • Ajanta Pharma Limited

第 17 章：策略建议

第 18 章：关于我们与免责声明

简介目录
Product Code: 15002

Global Malaria Therapeutics market is anticipated to grow considerably in the forecast period of 2028 due to the ongoing Investments in malaria research and development for eradicating malaria globally. According to the World Health Organization (WHO), in 2020, there were an estimated 229 million cases of malaria globally, with an estimated 409,000 deaths.

Malaria is a potentially life-threatening disease caused by parasites transmitted to humans through the bites of infected female mosquitoes. The parasites responsible for malaria are of the Plasmodium species, with Plasmodium falciparum being the most deadly. Malaria is prevalent in tropical and subtropical regions, particularly in sub-Saharan Africa, where it is a leading cause of morbidity and mortality. Treatment for malaria involves the use of antimalarial medications, which can vary depending on the type and severity of the infection. It is important to seek prompt medical attention if you suspect you have contracted malaria. Malaria is a serious disease and can be fatal if not treated promptly and appropriately.

Malaria therapeutics have a significant impact on patients who are infected with malaria. Malaria therapeutics help to alleviate the symptoms of the disease and prevent it from progressing to severe disease. Effective treatment can reduce the duration and severity of the illness, and prevent complications and long-term health problems. In addition to their direct impact on patients, malaria therapeutics also have broader impacts on public health and society, thereby supporting the growth of global malaria therapeutics market. Effective treatment can reduce the spread of the disease and prevent the development of drug-resistant strains of the parasite. This, in turn, can help to reduce the burden of the disease on healthcare systems and economies.

However, access to malaria therapeutics remains a significant challenge in many regions of the world where malaria is endemic, thereby hampering the growth of global malaria therapeutics market. Limited healthcare infrastructure, high treatment costs, and other barriers to access can prevent patients from receiving the care they need. Efforts to improve access to malaria therapeutics, such as through the development of affordable and accessible drugs and diagnostic tests, are crucial for improving patient outcomes and reducing the global burden of malaria. In 2020, 46 countries reported an increase in malaria cases, with 26 of these countries reporting more than a 20% increase. Children under the age of five are the most vulnerable group affected by malaria, accounting for an estimated 67% of all malaria deaths worldwide in 2020.

Growing incidence of malaria is boosting the Malaria Therapeutics Market

Increased demand for malaria therapeutics as the number of malaria cases increases, there is a greater demand for effective treatments. This presents a significant market opportunity for pharmaceutical companies developing malaria therapeutics.Malaria is a costly disease to treat, both in terms of direct medical expenses and lost productivity. As the incidence of malaria increases, healthcare systems may struggle to keep up with the demand for treatment and prevention, which could lead to increased costs. Malaria can cause severe illness and death, particularly among young children and pregnant women. The growing incidence of malaria means that more people are at risk of contracting the disease, which could lead to increased morbidity and mortality.

Malaria is a significant barrier to economic development in many countries, particularly those in sub-Saharan Africa. The disease can lead to lost productivity, increased healthcare costs, and decreased investment. As the incidence of malaria increases, these impacts may become more pronounced.

Malaria is a significant public health problem in many tropical and subtropical regions of the world, particularly in sub-Saharan Africa, where more than 90% of malaria cases and deaths occur. However, malaria also affects other parts of the world, including Asia, Latin America, and the Middle East. The incidence of malaria has been increasing in several countries in recent years, partly due to factors such as climate change, insecticide resistance, and the lack of access to effective prevention and treatment. In addition, political instability, Efforts to control and eliminate malaria include the use of insecticide-treated bed nets, indoor residual spraying, and antimalarial drugs. However, these efforts face several challenges, including limited funding, inadequate healthcare infrastructure, and the emergence of drug-resistant strains of the parasite.

Therefore, the growing incidence of malaria in several countries is a significant public health challenge that requires a comprehensive and sustained effort to address, thereby supporting the growth of global malaria therapeutics market.

Increasing investment in malaria research is Driving the Demand for Malaria Therapeutics in the Market

Increasing investment in malaria research is driving the demand for malaria therapeutics in the market. Investment in malaria research can lead to the development of new and improved malaria therapeutics, such as drugs and vaccines. These therapeutics can then be marketed and sold to individuals and organizations that are involved in the prevention and treatment of malaria.

In addition to driving demand for malaria therapeutics, increased investment in malaria research can also lead to the creation of new businesses and job opportunities in the pharmaceutical industry. This can have a positive impact on the economy and provide benefits for individuals and communities. Additionally, investment in malaria research is essential to address the global burden of malaria and improve the health outcomes of individuals who are affected by the disease. By driving demand for malaria therapeutics, such investment can play a critical role in achieving these goals.

Investment in malaria research can also lead to increased access to malaria interventions, such as mosquito nets, diagnostic tests, and antimalarial drugs. This can help prevent the spread of the disease and reduce the number of cases and deaths. Investment in malaria research can help strengthen health systems in malaria-endemic countries, leading to improved health outcomes for the population. This can include training healthcare workers, improving healthcare infrastructure, and increasing access to healthcare services.

Malaria disproportionately affects the most vulnerable populations, such as children under five and pregnant women. Increasing investment in malaria research can help reduce health inequities by improving access to prevention and treatment options for these populations.

Investment in malaria research can lead to the development of effective interventions such as vaccines, drugs, and insecticides. These interventions can then be used across multiple countries, leading to a reduction in the burden of malaria in those regions.

Furthermore, Investment in malaria research also lead to increased collaboration between researchers, healthcare providers, and governments across multiple countries. This collaboration can help share best practices and information, leading to better prevention and treatment of malaria across borders.

Additionally, Investment in malaria research can also have an impact on global health security. Malaria is a global health threat, and investing in research can help prevent the spread of the disease across borders and reduce the risk of epidemics.Malaria can cause significant morbidity, leading to long-term health problems in those who survive the disease. Investing in malaria research can help improve health outcomes by reducing the number of cases and the severity of the disease.

Favorable Government initiatives and Policies Drives the Malaria Therapeutics Market Growth

Favorable government initiatives and policies can play a significant role in driving the growth of the malaria therapeutics market. Malaria is a life-threatening disease that affects millions of people globally, particularly in developing countries. To combat the disease, governments across the world have launched various initiatives to promote the development and distribution of malaria therapeutics.

For instance, many governments have allocated significant funds for research and development activities focused on developing effective malaria therapeutics. In addition, governments have also launched programs to increase the accessibility of malaria medications to patients. This includes initiatives aimed at improving the supply chain, reducing the cost of medicines, and increasing awareness among patients.

Furthermore, various policies, such as tax incentives and regulatory frameworks, have been put in place to encourage investment in the global malaria therapeutics market. These policies can help to attract pharmaceutical companies and other stakeholders to invest in research and development activities, leading to the development of new and more effective malaria therapeutics. One of the most significant government initiatives is the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund is a partnership between governments, civil society, the private sector, and affected communities, and it provides funding for programs aimed at reducing the burden of malaria, among other diseases. In 2002, the Global Fund has committed over USD13 billion to malaria programs, and this funding has been crucial in supporting malaria control efforts worldwide.

Another important government initiative is the Roll Back Malaria Partnership, which is a global initiative aimed at coordinating and strengthening efforts to reduce the burden of malaria. The partnership is led by the World Health Organization and includes a wide range of stakeholders, including governments, international organizations, and civil society. Through the Roll Back Malaria Partnership, governments have committed to providing universal access to malaria prevention and treatment by 2030.

In addition to these global initiatives, many governments have also launched national programs aimed at combating malaria. For example, the government of Nigeria launched the National Malaria Elimination Program in 2016, with the goal of reducing the burden of malaria by 2020. The program includes a wide range of activities, such as the distribution of insecticide-treated bed nets, the provision of malaria diagnosis and treatment services, and the promotion of community-based interventions.

Governments have also implemented policies aimed at promoting the development and distribution of malaria therapeutics. For example, many countries have implemented policies aimed at reducing the cost of malaria medications. In some cases, governments have even provided free or subsidized medications to patients. In addition, many governments have implemented regulatory frameworks aimed at ensuring the quality and safety of malaria therapeutics.

Hence, the support of government initiatives has been crucial in driving the development and distribution of malaria therapeutics. These initiatives have provided funding and support for research and development activities, as well as for programs aimed at improving access to malaria prevention and treatment services. While there is still much work to be done in the fight against malaria, these government initiatives provide hope for a future where malaria is no longer a major public health concern. Hence creating lucrative opportunities for the growth of global malaria therapeutics market in the forecast period.

Market Segmentation

Global Malaria Therapeutics market is segmented based on drug type, drug formulation, distribution channel, and region. Based on drug type, global malaria therapeutics market is segmented into artemisinin-based combination therapy (ACT), quinine, chloroquine, and others. Based on drug formulation, the global malaria therapeutics market is fragmented into tablets, capsules, injectables, and Others. Based on distribution channel, the global malaria therapeutics market is segmented into retail pharmacies, hospitals, online pharmacies. Based on region, global malaria therapeutics market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.

Company Profiles

Novartis AG, Sanofi S.A, Pfizer Inc, GlaxoSmithKline Plc, Merck & Co Inc, F. Hoffmann-La Roche AG, Medicines for Malaria Venture, 60° Pharmaceuticals, Inc, Cipla Limited, Ajanta Pharma Limited are some of the key players of global malaria therapeutics market.

Report Scope:

In this report, global Malaria Therapeutics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

  • Malaria Therapeutics Market, By Drug Type:

Artemisinin-based combination therapy (ACT)

Quinine

Chloroquine

Others

  • Malaria Therapeutics Market, By Drug Formulatuion:

Tablets

Capsules

Injectables

Others

  • Malaria Therapeutics Market, By Distribution Channel:

Retail pharmacies

Hospitals

Online pharmacies

  • Malaria Therapeutics Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • France
  • Germany
  • United Kingdom
  • Spain
  • Italy

Asia-Pacific

  • India
  • South Korea
  • Japan
  • Australia
  • Vietnam
  • Indonesia
  • Myanmar

South America

  • Brazil
  • Colombia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Turkey
  • Nigeria

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in the global Malaria Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Malaria Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 6.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 6.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Product Map
    • 5.3.1 By Drug Type
    • 5.3.2 By Drug Formulation
    • 5.3.5 By Distribution Channel
    • 5.3.6 By Region

7. North America Malaria Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 7.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 7.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Malaria Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Drug Formulation
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Canada Malaria Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Drug Formulation
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Mexico Malaria Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Drug Formulation
        • 7.3.3.2.3. By Distribution Channel

8. Europe Malaria Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 8.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 8.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Malaria Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Drug Formulation
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Germany Malaria Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Drug Formulation
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. United Kingdom Malaria Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecasty
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Drug Formulation
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Italy Malaria Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Drug Formulation
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Spain Malaria Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Drug Formulation
        • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Malaria Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 9.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 9.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. India Malaria Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Drug Formulation
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Japan Malaria Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Drug Formulation
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Korea Malaria Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Drug Formulation
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. Australia Malaria Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Type
        • 9.3.4.2.2. By Drug Formulation
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Indonesia Malaria Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Type
        • 9.3.5.2.2. By Drug Formulation
        • 9.3.5.2.3. By Distribution Channel
    • 9.3.6. Vietnam Malaria Therapeutics Market Outlook
      • 9.3.6.1. Market Size & Forecast
        • 9.3.6.1.1. By Value
      • 9.3.6.2. Market Share & Forecast
        • 9.3.6.2.1. By Drug Type
        • 9.3.6.2.2. By Drug Formulation
        • 9.3.6.2.3. By Distribution Channel
    • 9.3.7. Myanmar Malaria Therapeutics Market Outlook
      • 9.3.7.1. Market Size & Forecast
        • 9.3.7.1.1. By Value
      • 9.3.7.2. Market Share & Forecast
        • 9.3.7.2.1. By Drug Type
        • 9.3.7.2.2. By Drug Formulation
        • 9.3.7.2.3. By Distribution Channel

10. South America Malaria Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 10.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 10.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Malaria Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Drug Formulation
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Malaria Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Drug Formulation
        • 10.3.2.2.3. By Distribution Channel

11. Middle East and Africa Malaria Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
    • 11.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
    • 11.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Malaria Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Type
        • 11.3.1.2.2. By Drug Formulation
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Saudi Arabia Malaria Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Type
        • 11.3.2.2.2. By Drug Formulation
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. UAE Malaria Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Type
        • 11.3.3.2.2. By Drug Formulation
        • 11.3.3.2.3. By Distribution Channel
    • 11.3.4. Turkey Malaria Therapeutics Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Drug Type
        • 11.3.4.2.2. By Drug Formulation
        • 11.3.4.2.3. By Distribution Channel
    • 11.3.5. Egypt Malaria Therapeutics Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Drug Type
        • 11.3.5.2.2. By Drug Formulation
        • 11.3.5.2.3. By Distribution Channel
    • 11.3.6. Nigeria Malaria Therapeutics Market Outlook
      • 11.3.6.1. Market Size & Forecast
        • 11.3.6.1.1. By Value
      • 11.3.6.2. Market Share & Forecast
        • 11.3.6.2.1. By Drug Type
        • 11.3.6.2.2. By Drug Formulation
        • 11.3.6.2.3. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
    • 12.1.1 High prevalence of malaria
    • 12.1.2 Growing Awareness
  • 12.2. Challenges
    • 12.2.1 High Cost and not always readily available
    • 12.2.2 Lack of Public Awareness

13. Market Trends & Developments

  • 13.1. Use of digital therapeutics
  • 13.2. Increasing use of genetic testing
  • 13.3. Increasing use of Combination Therapies

14. Global Malaria Therapeutics Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Product Offerings
  • 16.3. Recent Developments
  • 16.4. Financials (As Reported)
  • 16.5. Key Personnel
  • 16.6. SWOT Analysis
    • 16.6.1. Novartis AG
    • 16.6.2. Sanofi S.A
    • 16.6.3. Pfizer Inc
    • 16.6.4. GlaxoSmithKline Plc
    • 16.6.5. Merck & Co Inc
    • 16.6.6. F. Hoffmann-La Roche AG
    • 16.6.7. Medicines for Malaria Venture
    • 16.6.8. 60° Pharmaceuticals, Inc
    • 16.6.9. Cipla Limited
    • 16.6.10. Ajanta Pharma Limited

17. Strategic Recommendations

18. About Us & Disclaimer